Recent progress in the treatment of fulminant hepatic failure in Japan

Journal of Infection and Chemotherapy

Volumn 4, Issue 2, 1998, Pages 41-49

  Yoshiba, Makoto ^a  

^a SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

Author keywords

Fulminant hepatic failure; Hepatitis; Immunosuppressants; Treatment strategies

Indexed keywords

EID: 27144519277     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02489960     Document Type: Review

References (89)

1. Pack GT, Islami AH, Hubbard JL, Brasfield RD. Regeneration of human liver after major hepatectomy. Surgery 1962;52:617-623.
2. Yamanaka N, Okamoto E, Kawamura E, Kato T, Oriyama T, Fujimoto J, et al. Dynamics of normal and injured human liver regeneration after hepatectomy as assessed on the basis of computed tomography and liver function. Hepatology 18:1993:79-85.
3. Trey C, Davidson CS. The management of fulminant hepatic failure. In: Popper H, Schaffner F (eds) Progress in liver disease. Vol. 3. New York: Grune & Stratton, 1970: 282-298.
4. Di Bisceglie AM, Hoofnagle JH. Chronic viral hepatitis. In: Zakim D, Boyer TD (eds) Hepatology. A textbook of liver disease. 3rd ed. Philadelphia: WB Saunders, 1996: 1299-1328.
5. Sherlock S, Dooley J (eds). The haematology of liver disease. In: Diseases of the liver and biliary system. 10th Ed. London: Blackwell Science, 1997:43-62.
6. Muto Y. Fulminant hepatitis - is the survival improving? (editorial). Gastroenterol Jpn 1992;27:142-144.
7. Lidofsky SD. Fulminant hepatic failure. Crit Care Clin 1995;11:415-430.
8. Bernuau J, Benhamou J-P. Fulminant and subfulminant liver failure. In: McIntyre N, Benhamou J-P, Bircher J, Rizzetto M, Rodes J (eds) Oxford textbook of clinical hepatology. Oxford: Oxford Medical Publications, 1991: 921-944.
9. Scheuer PJ. Viral hepatitis. In: MacSween RNM, Anthony PP, Scheuner PJ (eds) Pathology of the liver. Edinburgh: Churchill Livingstone, 1987:202-223.
10. Ferrari C, Chisari FV. Immune mechanisms of cellular injury in viral hepatitis. In: Arias IM, Boyer JL, Fausto N, Jakoby WB, Schachter D, Shafriz DA (eds) The liver: biology and pathobiology. 3rd ed. New York: Raven Press, 1994:1413-1428.
11. Okamoto H, Nishizawa T, Kato M, Ukita H, Ikeda H, Iizuka H, et al. Molecular cloning and characterization of a novel DNA (TTV) associated with posttransfusion hepatitis of unknown etiology. Hepatol Res 1998;10;1-16.
12. Uchida T, Gotoh K, Shikata T. Complete nucleotide sequences and the characteristics of two hepatitis B mutants causing serologically negative acute or chronic hepatitis B. J Med Virol 1995;45:247-252.
13. Read AE. The liver and drugs. In: Wright R, Alberti KGMM, Karran S, Millward-Sadler GH (eds) Liver and biliary disease. London: Saunders, 1979:822-847.
14. Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol. JAMA 1994;272: 1845-1850.
15. Bass NM, Ockner RK. Drug-induced liver disease. In: Zakim D, Boyer TD (eds) Hepatology. A textbook of liver disease.Vol. 2. Philadelphia: WB Saunders, 1996:962-1017.
16. Rivera R, Slaughter RL, Boyce HW. Exchange transfusion in the treatment of patients with acute hepatitis in coma. Dig Dis Sci 1970;15:589-602.
17. Redeker AG, Yamahiro HS. Controlled trial of exchange transfusion therapy in fulminant hepatitis. Lancet 1973;1: 3-6.
18. Gazzard BG, Weston MJ, Murray-Lyon IM, Frax H, Record CD, Portmann B, et al. Charcoal haemoperfusion in the treatment of fulminant hepatic coma. Lancet 1974; 1:1301-1307.
19. Denis J, Opolon P, Nusinovici V, Granger A, Darnis F. Treatment of encephalopathy during fulminant failure by hemodialysis with high permeability membrane. Gut 1978; 19:787-793.
20. Stahl J. Studies of the blood ammonia in liver disease - its diagnostic, prognostic and therapeutic significance. Ann Intern Med 1963;58:1-24.
21. Ogiwara K, Mozai T, Hirai SN. Tryptophan as cause of hepatic coma. N Engl J Med 1966;275:1255-1256.
22. Cummings MG, James JH, Soeters PB, Keane JM, Foster J, Fischer JE. Regional brain study of indolamine metabolism in the rat in acute hepatic failure. J Neurochem 1976;27:741-746.
23. Fischer JE, Baldessarini RJ. False neurochemical transmitters and hepatic failure. Lancet 1971;2:75-79.
24. Challenger F, Walshe JM. Methylmercaptan in relation to fetor hepaticus. Biochem J 1955;59:372-375.
25. Muto Y. Clinical study on the short-chain fatty acids and hepatic encephalopathy. Jpn J Gastroenterol 1966;13:19-32.
26. Schafer DF, Jones EA. Hepatic encephalopathy and the gamma-aminobutyric acid neurotransmitter system. Lancet 1982;1:18-20.
27. Zeive L. The mechanism of hepatic coma. Hepatology 1981;1:360-365.
28. Lepore M, Martel A. Plasmapheresis in hepatic coma. Lancet 1967;2:771-772.
29. Opolon P. Significance of middle molecules in the pathogenesis of hepatic encephalopathy. In: Kleinberger G, Ferenci P, Riederer P, Thuler H (eds) Advances in hepatic encephalopathy and urea cycle diseases. Basel: Karger, 1984:310-314.
30. O'Grady JG, Gimson AES, O'Brien CJ, Pucknell A, Hughes RD, Williams R. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988;94:1186-1192.
31. Yamazaki Z, Fujimori Y, Sanjo K, Kojima Y, Sugiura M, Wada J, et al. New artificial liver support system (plasma perfusion detoxification) for hepatic coma. Artif Organs 1978;2(suppl):273-276.
32. Yoshiba M, Sanjo T, Yamazaki Z, Inoue N, Sakai T, Okada Y, et al. Aggravation of coagulation abnormality by charcoal plasma perfusion in dogs with experimental acute liver failure. Acta Hepatol Jpn 1983;24:426-431.
33. Iwatsuki S, Stieber AC, Marsh JW. Liver transplantation for fulminant hepatic failure. Transplant Proc 1989;21: 2431-2434.
34. Shimahara Y, Awane M, Yamoka Y, Tanaka A, Morimoto T, Mori K, et al. Analyses of the risk and operative stress for donors in living-related partial liver transplantation. Transplantation 1992;54:983-988.
35. McCaughan GW. Selection of patients for liver transplantation. J Gastroenterol Hepatol 1993;8:185-194.
36. Wiesner RH, Ludwig J, van Hoek B. Current concepts in cell-mediated hepatic allograft rejection leading to ductopenia and liver failure. Hepatology 1991;14:721-729.
37. Gholson CF, McDonald J, MacMillan R. Liver transplantation. Postgrad Med 1995;97:101-114.
38. Starzl TE, Koep LJ, Halgrimson CG, Hood J, Schroter CPJ, Porter KA, et al. Fifteen years of clinical liver transplantation. Gastroenterology 1979;77:375-388.
39. Chapman RW, Forman D, Peto R, Smallwood R. Liver transplantation for acute hepatic failure? Lancet 1990;335: 32-35.
40. Yoshiba M, Inoue N, Sanjo T, Yamazaki Z, Okada Y, Oda T, et al. Plasmapheresis in acute liver failure. In: Nose Y, Malchelsky PS, Smith JW, Krakauer RS (eds) Plasmapheresis therapeutic applications and new techniques. New York: Raven Press, 1983:399-406.
41. Yoshiba M, Yamada H, Yoshikawa Y, Fujiwara K, Toda G, Oka H, et al. Hemodiafiltration treatment of deep hepatic coma by protein passing membrane: case report. Artif Organs 1986;10:417-421.
42. Yoshiba M, Sekiyama K, Iwamura Y, Sugata F. Development of reliable artificial liver support (ALS) - plasma exchange in combination with hemodiafiltration using high-performance membrane. Dig Dis Sci 1993;38:469-476.
43. Yoshiba M, Inoue K, Sekiyama K, Koh I. Favorable effect of new artificial liver support on survival of patients with fulminant hepatic failure. Artif Organs 1996;20: 1169-1172.
44. Inaba S, Kishikawa T, Zaitsu A, Ishibashi H, Kudo J, Ogawa R, et al. Continuous haemoperfusion for fulminant hepatic failure. Lancet 1991;338:1342-1343.
45. Sekiyama K, Yoshiba M, Inoue K, Sugata F. Prognostic value of hepatic volumetry in fulminant hepatic failure. Dig Dis Sci 1994;39:240-244.
46. Rozca J, Demetriou AA. Artificial liver evolution and future perspectives. ASAIO J 1995;41:831-837.
47. Nelson SD. Molecular mechanisms of the hepatotoxicity caused by acetaminophen. Semin Liver Dis 1990;10:267-278.
48. Fried MW. The liver in systemic illness. In: Zakim D, Boyer TD (eds) Hepatology. A textbook of liver disease. 3rd ed. Philadelphia: WB Saunders, 1996:1706-1725.
49. Rumack BH, Peterson RC, Koch GG, Amara IA. Acetaminophen overdose: 662 cases with evaluation of oral acetylcysteine treatment. Arch Intern Med 1981;141:380-385.
50. Dudley FJ, Fox RA, Sherlock S. Cellular immunity in hepatitis associated Australia antigen disease. Lancet 1972; 1:723-726.
51. Brechet C, Bernuau J, Thiers V. Multiplication of hepatitis B virus in fulminant hepatitis B. Br Med J (Clin Res Ed) 1984;288:270-271.
52. Cock KM, Govindarajan S, Valinluck B. Hepatitis B DNA in fulminant hepatitis B. Ann Intern Med 1986;105:546-547.
53. Levin S, Hahn T. Interferon system in acute viral hepatitis. Lancet 1982;1:592-594.
54. Sanches-Tapias JM, Mas A, Costa J. Recombinant α2C-interferon therapy in fulminant viral hepatitis. J Hepatol 1987;5:205-210.
55. Milazzo F, Galli M, Fassio G. Attempted treatment of fulminant viral hepatitis with human fibroblast interferon. Infection 1985;13:130-133.
56. Thung SN, Gerber MA, Klion F, Gilbert H. Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B virus carrier. Arch Intern Med 1985;145:1313-1314.
57. Pariente EA, Goudeau A, Dubois F, Devergie A, Brechot C, Schenmetzler C, et al. Fulminant hepatitis due to reactivation of chronic hepatitis B virus infection after allogenic bone marrow transplantation. Dig Dis Sci 1992;37:1253-1259.
58. Lok ASF, Liang RHS, Chiu EKW, Wong K-L, ChanT-K, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Gastroenterology 1991;100:182-188.
59. Yoshiba M, Sekiyama K, Sugata F, Okamoto H, Yamamoto K, Yotsumoto S. Reactivation of precore mutant hepatitis B virus leading to fulminant hepatic failure following cytotoxic treatment. Dig Dis Sci 1992;37:1253-1259.
60. Inoue K, Yoshiba M, Sekiyama K, Okamoto H, Mayumi M. Clinical and molecular differences between fulminant hepatic failures following acute and chronic infection with hepatitis B virus. J Med Virol 1998;55:35-41.
61. Muto Y, Sugihara J, Ohnishi H, Moriwaki H, Nishioka K. Anti-hepatitis C virus prevails in fulminant hepatic failure. Gastroenterol Jpn 1990;25:32-35.
62. Yoshiba M, Sekiyama K, Sugata F, Okamoto H, Mayumi M. Persistence of HCV replication in non-A, non-B fulminant viral hepatitis (letter). Gastroenterol Jpn 1991;26:235.
63. Yanagi M, Kaneko S, Unoura M, Murakami S, Kobayashi K, Sugihara J, et al. Hepatitis C virus in fulminant hepatic failure (letter). N Engl J Med 1991;324:1985.
64. Yoshiba M, Sekiyama K, Inoue K, Okamoto H, Mayumi M. Contribution of hepatitis C virus to non-A, non-B fulminant hepatitis in Japan. Hepatology 1994;19:829-835.
65. Villami FG, Hu K-Q, Yu C-H, Lee C-H, Rojter SE, Podesta LG. Detection of hepatitis C virus with RNA polymerase chain reaction in fulminant hepatic failure. Hepatology 1995;22:1379-1386.
66. Farci P, Alter HJ, Shimoda A, Govindarajan S, Cheung L, Melpolder JC, et al. Hepatitis C virus-associated fulminant hepatic failure. N Engl J Med 1996;335:631-634.
67. Yoshiba M, Okamoto H, Mishiro S. Detection of the GBV-C hepatitis virus genome in serum from fulminant hepatitis of unknown aetiology. Lancet 1995;346:1131-1132.
68. Heringlake S, Osterkamp S, Trautwein C, Tillman HL, Boker K, Muerhoff S, et al. Association between fulminant hepatic failure and a strain of GBV virus C. Lancet 1996;348:1626-1629.
69. Wright TL, Hsu H, Donegan E, Feinstone S, Greenberg H, Read A, et al. Hepatitis C virus not found in fulminant non-A, non-B hepatitis. Ann Intern Med 1991;115:111-112.
70. Feray C, Gigou M, Samuel D, Reyes G, Bernuau J, Reynes M, et al. Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis. Gastroenterology 1993;104:549-555.
71. Kuwada SK, Patel VM, Hollinger B, Yarbough PD, Wiesner R, Kaeses D, et al. Non-A, non-B fulminant hepatitis is also non-E and non-C. Am J Gastroenterol 1994;89:57-61.
72. Kuroki T, Nishiguchi S, Tanaka T, Enomoto M, Kobayashi K. Does GBV-C cause fulminant hepatitis in Japan? (letter) Lancet 1996;347:908.
73. Kanda T, Yokosuka O, Ehata T, Maru Y, Imazeki F, Saisho H, et al. Detection of GBV-C RNA in patients with non-A-E fulminant hepatitis by reverse-transcription polymerase chain reaction. Hepatology 1997;25(5):1261-1265.
74. Farci P, Alter HJ, Govindarajan S, Wong DL, Engle R, Lesniewski RR, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992;258:135-140.
75. Weiner AJ, Geysen M, Christopherson C, Hall JE, Mason TJ, Saracco M, et al. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci U S A 1992;89:3468-3742.
76. Karayanis P, Petrovic LM, Fry M, Moor D, Enticott M, McGarvey MJ, et al. Studies of GB hepatitis agent in tamarins. Hepatology 1989;9:186-192.
77. Linnen J, Wages J, Zang-Keck Z-Y, Fry KE, Krawczynski K, Alter H, et al. Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 1995;271:505-508.
78. Mathiesen LR, Skinoj P, Nielsen JD, Purcell RH, Wong D, Rakela L. Hepatitis type A, type B and non-A, non-B fulminant hepatitis, Gut 1980;21:72-77.
79. Gimson AES, White YS, Eddelston AIWF. Clinical and prognostic differences in fulminant type A, B, and non-A, B, and non-A non-B. Gut 1983;24:1194-1198.
80. Takahashi Y, Shimizu M, and the study group of fulminant hepatitis. Aetiology and prognosis of fulminant viral hepatitis in Japan: a multicentre study. J Gastroenterol Hepatol 1991;6:159-164.
81. Woolf I, Elsheikh N, Cullens H. Enhanced HBsAb production in pathogenesis of fulminant viral hepatitis type B. Br Med J 1976;II:669-671.
82. Trepo CG, Robert D, Motin J. Hepatitis B antigen (HBsAg) and/or antibodies (anti-HBs and anti-HBc) in fulminant hepatitis: pathogenic and prognostic significance. Gut 1976;17:10-13.
83. Webster A, Brenner MK, Prentice HG, Griffith PD. Fatal hepatitis B reactivation after autologous bone marrow transplantation. Bone Marrow Transplant 1989;4:207-208.
84. Onwubalili JK. Fulminant hepatic failure in nephrotic syndrome related to withdrawal of immunosuppressive therapy. Postgrad Med J 1988;64:325-327.
85. Hanson CA, Sutherland DE, Snover DC. Fulminant hepatic failure in an HBsAg carrier renal transplant patient following cessation of immunosuppressive therapy. Transplantation 1985;39:311-312.
86. Yoshiba M, Sekiyama K, Iwabuchi S, Takatori M, Tanaka F, Uchikoshi T, et al. Recurrent fulminant hepatic failure in an HB carrier after intensive chemotherapy. Dig Dis Sci 1993;38:1751-1755.
87. Rakela J, Mosley JW, Edwards VM, Govindarajan S, Alpert E. A double-blinded, randomized trial of hydrocortisone in acute hepatic failure. Dig Dis Sci 1991;36:1223-1228.
88. Yoshiba M, Sekiyama K, Inoue K, Fujita R. Interferon and cyclosporin A in the treatment of fulminant viral hepatitis. J Gastroenterol 1995;30:67-73.
89. O'Grady, Alexander GJM, Hayllar KM. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439-445.